Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma

Abstract

Aim: Despite aggressive multiagent protocols, patients with metastatic rhabdomyosarcoma (RMS) have poor prognosis. In a recent high-risk trial (ARST0431), 25% of patients failed within the first year, while on therapy and 80% had tumor progression within 24 months. However, the mechanisms for tumor resistance are essentially unknown. Here we explore the use of preclinical models to develop resistance to complex chemotherapy regimens used in ARST0431.

Methods: A Single Mouse Testing (SMT) protocol was used to evaluate the sensitivity of 34 RMS xenograft models to one cycle of vincristine, actinomycin D, cyclophosphamide (VAC) treatment. Tumor response was determined by caliper measurement, and tumor regression and event-free survival (EFS) were used as endpoints for evaluation. Treated tumors at regrowth were transplanted into recipient mice, and the treatment was repeated until tumors progressed during the treatment period (i.e., became resistant). At transplant, tumor tissue was stored for biochemical and omics analysis.

Results: The sensitivity to VAC of 34 RMS models was determined. EFS varied from 3 weeks to > 20 weeks. Tumor models were classified as having intrinsic resistance, intermediate sensitivity, or high sensitivity to VAC therapy. Resistance to VAC was developed in multiple models after 2-5 cycles of therapy; however, there were examples where sensitivity remained unchanged after 3 cycles of treatment.

Conclusion: The SMT approach allows for in vivo assessment of drug sensitivity and development of drug resistance in a large number of RMS models. As such, it provides a platform for assessing in vivo drug resistance mechanisms at a “population” level, simulating conditions in vivo that lead to clinical resistance. These VAC-resistant models represent “high-risk” tumors that mimic a preclinical phase 2 population and will be valuable for identifying novel agents active against VAC-resistant disease.

Keywords

Rhabdomyosarcoma / patient-derived xenografts / combination therapy / intrinsic drug resistance / acquired drug resistance

References

[1] Malempati S.Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies.Pediatr Blood Cancer2012;59:5-10 PMCID:PMC4008325

[2] Oberlin O,Lyden E.Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups.J Clin Oncol2008;26:2384-9 PMCID:PMC4558625

[3] Breneman JC,Pappo AS.Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV.J Clin Oncol2003;21:78-84

[4] Weigel BJ,Hawkins D,Baker KS.Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma.J Pediatr Hematol Oncol2001;23:272-6

[5] Weigel BJ,Anderson JR.Intensive multiagent therapy, including dose-compressed cycles of ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide, irinotecan, and radiation, in patients with high-risk rhabdomyosarcoma: a report from the Children's Oncology Group.J Clin Oncol2016;34:117-22 PMCID:PMC5070550

[6] Chen X,Shelat AA.StJude Children’s Research Hospital-Washington University Pediatric Cancer Genome Project. Targeting oxidative stress in embryonal rhabdomyosarcoma.Cancer Cell2013;24:710-24 PMCID:PMC3904731

[7] Horton JK,Houghton JA.Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard.Cancer Res1987;47:6288-93

[8] Houghton JA,Brodeur GM.Development of resistance to vincristine in a childhood rhabdomyosarcoma growing in immune-deprived mice.Int J Cancer1981;28:409-15

[9] Jones M,Kelland LR.Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.Br J Cancer1993;67:24-9 PMCID:PMC1968234

[10] Yamamoto TM,Watson ZL.Activation of Wnt signaling promotes olaparib resistant ovarian cancer.Mol Carcinog2019;58:1770-82 PMCID:PMC7537108

[11] Gay CM,Park EM.Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.Cancer Cell2021;39:346-360.e7 PMCID:PMC8143037

[12] Ricci F,Affatato R.Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts.Ther Adv Med Oncol2019;11:1758835919839543 PMCID:PMC6591669

[13] Kim K,Audenet F.Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts.Nat Commun2020;11:1975 PMCID:PMC7181640

[14] Ghilu S,Houghton PJ.Developing new agents for treatment of childhood cancer: challenges and opportunities for preclinical testing.J Clin Med2021;10:1504 PMCID:PMC8038510

[15] Houghton PJ,Tucker C.The pediatric preclinical testing program: description of models and early testing results.Pediatr Blood Cancer2007;49:928-40

[16] Houghton P,Erickson S.Prospective validation of single mouse testing (SMT) by the pediatric preclinical testing consortium (PPTC).Eur J Cancer2020;138:S18

[17] Ghilu S,Fontaine SD.Prospective use of the single-mouse experimental design for the evaluation of PLX038A.Cancer Chemother Pharmacol2020;85:251-63 PMCID:PMC7039322

[18] Murphy B,Maris JM.Evaluation of alternative in vivo drug screening methodology: a single mouse analysis.Cancer Res2016;76:5798-809 PMCID:PMC5050128

[19] Rokita JL,Cardenas MF.Genomic profiling of childhood tumor patient-derived xenograft models to enable rational clinical trial design.Cell Rep2019;29:1675-89.e9 PMCID:PMC6880934

[20] Stewart E,Karlstrom A.The childhood solid tumor network: a new resource for the developmental biology and oncology research communities.Dev Biol2016;411:287-93 PMCID:PMC4600003

[21] Peng KW,Greenslade A.Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.Gene Ther2013;20:255-61 PMCID:PMC3806053

[22] Nair AB.A simple practice guide for dose conversion between animals and human.J Basic Clin Pharm2016;7:27-31 PMCID:PMC4804402

[23] Crom WR,Synold T.Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia.J Pediatr1994;125:642-9

[24] Houghton PJ,Myers L,Synold TW.Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.Cancer Chemother Pharmacol1992;31:229-39

[25] Pappo AS,Breitfeld P.Children's Oncology GroupTwo consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.J Clin Oncol2007;25:362-9

[26] Hawkins DS,Anderson JR.Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the children's oncology group.J Clin Oncol2018;36:2770-7 PMCID:PMC6145831

[27] Mascarenhas L,Lyden E.Soft Tissue Sarcoma CommitteeChildren's Oncology GroupRandomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine (V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma (RMS): a report from the Children’s Oncology Group (COG).J Clin Oncol2014;32:10003

[28] Minard-Colin V,Nguyen L.Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma--a report from the Société Française des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE).Eur J Cancer2012;48:2409-16

[29] Kuttesch JF,Luo X.P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma.J Clin Oncol1996;14:886-900

[30] Hettmer S,Somers GR.Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers.Cancer2014;120:1068-75 PMCID:PMC4173134

[31] Qualman S,Bridge J.Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.Cancer2008;113:3242-7 PMCID:PMC2727712

[32] Rosenberg AR,Lyden E.Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group.Eur J Cancer2014;50:816-23

[33] Vaarwerk B,Breunis WB.Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: a report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study.Cancer2018;124:1016-24

[34] Wang L,Bondra K.SNAI2-mediated repression of BIM protects rhabdomyosarcoma from ionizing radiation.Cancer Res2021;81:5451-63 PMCID:PMC8669772